• Qualitative detection of NMO22 in urine samples
• Rapid test for bladder cancer screening
• Test result can be read after approx. 15 minutes
• Simple visual interpretation without additional devices
• 10 test cassettes and 10 disposable pipettes

NADAL® Nuclear Matrix Protein 22 Test

The NADAL® Nuclear Matrix Protein 22 (NMP22) Test from nal von Minden is a reliable in-vitro immunoassay for the qualitative detection of Nuclear Mitotic Apparatus Protein (NuMA) in urine. This professional rapid test offers doctors a simple and hygienic method for bladder cancer screening and monitoring, with results available in approximately 15 minutes.

Product Details

• NADAL® Nuclear Matrix Protein 22 from nal von Minden
• Reliable and hygienic in-vitro immunoassay
• Qualitative detection of Nuclear Mitotic Apparatus Protein (NuMA)
• Professional rapid test for bladder cancer screening
• Applicable for monitoring as well
• Sample material: Urine
• Detected parameter: Nuclear Matrix Protein 22
• Results readable in about 15 minutes
• Simple visual interpretation without additional devices
• Includes integrated procedural control
• Storage at room temperature (2-30 °C)
• CE marked
• Includes 10 disposable pipettes and a user manual
• 10 tests

Performance Characteristics

To obtain data on diagnostic sensitivity and specificity, urine from 32 patients with biopsy-confirmed bladder cancer and 112 healthy individuals without bladder tumours was tested with the NADAL® Nuclear Matrix Protein 22 Test. The results are shown in the table below: